Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Intestinal Behçet's disease~* Patients with typical ulcer at ileocecal region~* Patients who have failed conventional treatment~Exclusion Criteria:~* Crohn's disease~* History of ileocecal resection~* History of tuberculosis (TB)~* Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.

Based on this trial design, predict the completion outcome and termination type (if applicable).